Decision & Strategy for Business Support" encapsulates the core essence of DGS Capital Group. It reflects our unwavering commitment to making astute, strategic investment decisions that serve as catalysts for growth within our diverse portfolio companies. Across real estate, cutting-edge technology & AI, pharmaceuticals, and the specialized veterinary sectors, our approach is always rooted in thoughtful analysis and a proactive drive for expansion and innovation.
Diego Garcia brings over 15 years of extensive experience in investment management, underpinned by a Bachelor's in Business & Economics and an MBA. As the visionary CEO of Santgar, he orchestrated its transformation into a major international pharmaceutical company, leaving an indelible mark on the industry.
DGS Capital Group was founded in 2022 as a holding company focused on innovation across fast growing industries, laying the foundation for long term impact.
Secured over $50 million in investments to scale DGS Capital Group’s portfolio companies and expand their presence across key markets.
Led programs that trained more than 1,000 veterinarians in Mexico, helping improve their business operations and long term clinic performance.
Formed a key alliance with a major Mexican bank to support over 200 clinics through smart debt financing and improved financial tools.
We back high-growth companies in veterinary care, biotech, and tech—each chosen for their market impact and long-term potential.
Diego Garcia’s expertise has been featured in outlets like *Entrepreneur Magazine*, with appearances at events such as the Global Investment Summit and on podcasts like *The Future of Business*, where he shares insights on cross-industry investment strategies.
Miami, Florida--(Newsfile Corp. - February 7, 2023) - Leading Mexican veterinary pharmaceutical firm Santgar announced today the upcoming availability of Excentera LS, a new medical product to treat immune-mediated disease in dogs that cause dry eye.
Read More
With drug innovation for pets becoming increasingly important, Santgar is taking a proactive approach to providing novel solutions geared to fulfill the demands of veterinary practitioners and pet owners
Read More
Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
Read More Miami, Florida--(Newsfile Corp. - February 7, 2023) - Leading Mexican veterinary pharmaceutical firm Santgar announced today the upcoming availability of Excentera LS, a new medical product to treat immune-mediated disease in dogs that cause dry eye.
Read More With drug innovation for pets becoming increasingly important, Santgar is taking a proactive approach to providing novel solutions geared to fulfill the demands of veterinary practitioners and pet owners
Read More Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
Read More
Fill out the form and we’ll get back to you soon. We're here to help with any questions or ideas.
